| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Linalool — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile terpene found in many essential oils, including lavender, coriander, basil, rosewood, and citrus-associated oils. It is formally classified as a small-molecule phytochemical / monoterpenoid fragrance and flavor compound, commonly abbreviated as LIN or Lin. It exists as enantiomers with different odor profiles and biological handling. In oncology research, linalool is best treated as a preclinical bioactive terpene with in-vitro and limited animal-model anticancer signals, not as a clinically validated anticancer therapy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Linalool is volatile and lipophilic, with systemic exposure possible after oral, inhaled, and transdermal routes, but therapeutic plasma levels for anticancer effects remain uncertain. Human oral PK methods have been developed, and inhalation/transdermal studies support absorption, but most anticancer experiments use concentrations that are difficult to map directly to achievable human exposure. In-vitro vs systemic exposure relevance: Many anticancer studies use high micromolar to millimolar linalool concentrations, especially in lung, liver, leukemia, prostate, and colon cancer cell models. These levels may exceed realistic systemic exposure from food, fragrance, aromatherapy, or ordinary essential-oil use. Direct anticancer interpretation should therefore be concentration-constrained. Clinical evidence status: Preclinical. Linalool itself has no established cancer-treatment indication. Human studies involving linalool-rich essential oils or aromatherapy are mainly supportive-care studies for anxiety, sleep, pain, or procedural distress, not tumor-response trials. Regulatory status is primarily as a flavor/fragrance substance, not as an approved oncology drug. Linalool Cancer Mechanism Table
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Proliferating Cell Nuclear Antigen (PCNA) is a protein that plays a crucial role in DNA replication and repair. It acts as a processivity factor for DNA polymerase, helping to increase the efficiency of DNA synthesis. PCNA is also involved in various cellular processes, including cell cycle regulation, DNA damage response, and chromatin remodeling. PCNA is often overexpressed in many types of tumors. This overexpression is associated with increased cell proliferation, which is a hallmark of cancer. The elevated levels of PCNA can serve as a biomarker for tumor growth and progression. PCNA is called the “ringmaster of the genome” : it regulates the cell cycle and participates in DNA synthesis. PCNA is widely used as a cell proliferation marker in both healthy and malignant tissues. |
| 6481- | LIN, | Linalool inhibits 22Rv1 prostate cancer cell proliferation and induces apoptosis |
| - | in-vivo, | Pca, | 22Rv1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:410 Target#:489 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid